Last reviewed · How we verify
NCT04522739: STAND
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia
Phase 4 trial testing Spironolactone in Mild Cognitive Impairment in 25 participants. Completed in 23 September 2025.
23 September 2025
Quick facts
| Lead sponsor | Emory University |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 25 |
| Start date | 6 September 2022 |
| Primary completion | 23 September 2025 |
| Estimated completion | 23 September 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Spironolactone (spironolactone) — full drug profile →
- Placebo
Conditions studied
- Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
- Alzheimer Disease — all drugs for Alzheimer Disease →
Sponsor
Emory University
Who can join
50 and older, any sex, with Mild Cognitive Impairment or Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to investigate whether a blood pressure medication, spironolactone, can be tolerated by older African American adults that have memory and thinking problems, also called mild cognitive impairment (MCI). This study will also investigate the effect of spironolactone on memory and thinking abilities as measured by performance on cognitive tests, which are tests that measure memory and thinking skills. Participants will take spironolactone or a placebo for one year and will have 4 to 5 study visits during the study period.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets.
Gao C, Jiang J, Tan Y, Chen S. · · 2023 · cited 998× · PMID 37735487 · DOI 10.1038/s41392-023-01588-0 -
Clinical trials of new drugs for Alzheimer disease: a 2020-2023 update.
Huang LK, Kuan YC, Lin HW, Hu CJ. · · 2023 · cited 165× · PMID 37784171 · DOI 10.1186/s12929-023-00976-6 -
Sildenafil as a Candidate Drug for Alzheimer's Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons.
Gohel D, Zhang P, Gupta AK, Li Y, et al · · 2024 · cited 13× · PMID 38427489 · DOI 10.3233/jad-231391 -
Dual impact of neuroinflammation on cognitive and motor impairments in Alzheimer's disease.
Fakorede S, Lateef OM, Garuba WA, Akosile PO, et al · · 2025 · cited 9× · PMID 40463291 · DOI 10.1177/25424823251341870
Verify or expand the search:
- PubMed search for NCT04522739
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Spironolactone
Trials testing the same drug.
- NCT07020104 — The Role of Skin Sodium Accumulation in Chronic Kidney Disease · NA · recruiting
- NCT06204640 — SPironolactONe for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation · Phase 3 · not yet recruiting
- NCT06164379 — Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism · Phase 4 · unknown
- NCT06004830 — Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 1 · Phase 2 · active not recruiting
- NCT06641284 — Gender-Based Differences in Heart Failure Hospitalizations Among Patients With Heart Failure Treated With Spironolactone · completed
Other recruiting trials for Mild Cognitive Impairment
Currently open trials in the same condition.
- NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
- NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
- NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting
Other Emory University trials
Trials by the same sponsor.
- NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
- NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
- NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
- NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
- NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04522739 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Emory University
- Last refreshed: 29 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04522739.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing